STAT+: Cortexyme bets a lower dose of its once-failed Alzheimer’s drug can work in another trial
Cortexyme, pressing forward after its novel approach to Alzheimer’s disease failed in a mid-stage trial,…
Category: STAT+
STAT+: Pharmalittle: NIH to fight Moderna in court over Covid-19 vaccine patents; ‘puzzling’ results in an Alzheimer’s study
Rise and shine, another busy day is on the way. We can tell because our…
.jpg)
STAT+: ‘Quite puzzling’ results in Alzheimer’s study cloud future of tau-targeting antibody treatment
New clinical trial results may temper early hope for an experimental Genentech treatment that targets…
STAT+: Pharmalittle: Moderna and NIH clash over Covid-19 vaccine patent; Biogen probes Alzheimer’s patient death
Good morning, everyone, and how are you today? We are doing just fine, thank you,…
STAT+: Company that sold overdose antidote to pay $12.7 million to settle charges of fraudulent scheme
Kaleo, a small and controversial company, agreed to pay $12.7 million to resolve allegations that…
STAT+: Obesity journal editor’s extensive company ties raise concerns about conflicts of interest in publishing
Over the past seven years, a top editor at a medical journal devoted to obesity…
STAT+: Oklahoma court overturns $465 million opioid verdict against Johnson & Johnson
The Oklahoma Supreme Court overturned a $465 million judgment against Johnson & Johnson (JNJ) in…
STAT+: Anti-aging research foundation stands by ouster of Aubrey de Grey after investigation concludes
Aubrey de Grey, the anti-aging research pioneer who was removed in August as chief scientific…
STAT+: STAT+ Conversation: Drug pricing drama
Editor’s note: A livestream of the conversation will be embedded below at 1 p.m. ET….
STAT+: Pharmalittle: Pelosi was the real holdout in drug-pricing talks; U.S. to pay $1 billion for more Merck Covid pills
Hello, everyone, and how are you this morning? Despite some tech challenges today, we are…
STAT+: Can David Feinberg fix Cerner? The new CEO of an electronic health record giant faces fresh threats
In many ways, David Feinberg was an unconventional choice to lead Cerner, one of the…
STAT+: A controversial drug for premature births, which FDA wants withdrawn, is tied to elevated cancer risk
The key ingredient in a controversial medicine used to prevent premature births is associated with a…
STAT+: Hospitals charge insurers and cash-paying patients much more than what Medicare pays for some infused drugs
Nearly a dozen of the highest-rated hospitals in the U.S. charged commercial health insurers and…
STAT+: More lung cancer patients see tumor responses with Mirati’s KRAS combination treatment
Mirati Therapeutics said Monday that more than 60% of patients with lung cancer showed confirmed…
STAT+: Pharmalittle: Court rulings on 340B drug discounts conflict; Swiss socialists want government to buy Sandoz
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
Opinion: STAT+: Why does the FDA want to stop improving medicines via patent ‘areas of concern’?
It’s hardly unprecedented for one federal agency to encroach on another’s turf. But the latest intra-executive-branch…
STAT+: Moderna millionaires and the double-edged sword of stock market riches
In just a few years, Moderna went from stock market dud to moonshot, a prime example…
STAT+: New court rulings add to the confusing and controversial dispute over a U.S. drug discount program
In the latest twist in a closely watched legal battle, two different federal court judges…
STAT+: Clinical trial sites face challenges in diversifying personnel and participants, study finds
As demands for diversity and equity increase across the globe, a new analysis finds nearly…
STAT+: Pharmalittle: Pfizer pill reduced deaths in newly diagnosed Covid patients; U.S. cancels contract with Emergent
Good morning, and a fine Friday to you from STAT reporter Andrew Joseph, here filling…
STAT+: John Maraganore on what comes next for Alnylam and his career
This interview is an excerpt from a recent segment on “The Readout LOUD.” Listen to…
STAT+: Alphabet has a new drug discovery company building on DeepMind’s AI chops
Alphabet is plunging into the drug discovery business. Over the last year, the tech behemoth…
STAT+: Pharmalittle: Moderna sees $18 billion in Covid vaccine sales despite production woes; U.K. clears Merck Covid pill
Good morning, folks. And how are you today? We are in fine spirits, thanks to…
STAT+: CAR-T therapies from Bristol, Gilead superior to standard treatment in blood cancer, studies show
Administering bespoke CAR-T cell therapies from Bristol Myers Squibb or Gilead Sciences provides greater benefit…
STAT+: Alzheimer’s conference preview: Aduhelm debate persists, while field grapples with new targets and directions
When physicians and scientists involved in Alzheimer’s disease gather in Boston next week for an…
STAT+: ‘The beginning of a long journey’: A progress report on Big Retail’s ambitions in health care
When Mark Wahlberg helped ring in the grand opening of Walmart’s second health clinic in…
STAT+: Scientists find a clue to why some people have ‘Alzheimer’s brains’ but no dementia
Defective proteins clump into toxic plaques and tangles. Plaques of amyloid and tau tangles kill…
STAT+: Pharmalittle: Democrats reach a deal on drug pricing; CDC OKs Pfizer Covid shot for kids ages 5 to 11
Rise and shine, everyone, another busy day is on the way. Yes, indeed, the middle…
STAT+: Pharmalittle: Pfizer expects $36 billion in Covid-19 vaccine sales this year; Dems scramble for a drug-pricing compromise
Top of the morning to you. Gray skies are hovering over the Pharmalot campus right…
STAT+: STAT+ Conversation: Intelligence about artificial intelligence
Editor’s note: A livestream of the conversation will be embedded below at 1 p.m. ET….
STAT+: Moderna, making billions from its vaccine, bets on a genome-editing startup
Moderna, flush with cash thanks to its blockbuster Covid-19 vaccine, made waves back in August…
STAT+: Could Robert Califf’s ties to tech complicate his FDA nomination?
WASHINGTON — Robert Califf spent his first confirmation hearing explaining his entanglements with the drug…
STAT+: With two new insurance partnerships, EQRx takes its first steps toward lowering drug prices. But how big are those steps?
EQRx — the buzzy biotech company with a lofty mission of making far less expensive…
STAT+: In a first, a California judge rules drug makers are not liable for the opioid crisis
For the first time, drug makers won a court victory in the massive litigation over…
STAT+: Pharmalittle: Doctors pushing Alzheimer’s drug have ties to Biogen; pharma wins key round in dispute over hospital discounts
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Centessa drug shows early promise for inherited lung disease, but liver safety issue seen in small study
An experimental “corrector” drug from Centessa Pharmaceuticals normalized the levels of a target protein in…
.jpg)
STAT+: The Purdue bankruptcy plan was approved to distribute billions. Where is the money?
Nearly two months ago, a U.S. bankruptcy court judge approved a controversial Purdue Pharma plan…
STAT+: The loudest physician proponents of Aduhelm have all taken money from Biogen
WASHINGTON — A small group of physicians with deep, at times undisclosed, financial ties to…
STAT+: Government’s bid to force drug makers to offer discounts to some hospitals was ‘arbitrary and capricious,’ judge rules
After more than a year of controversy, a federal court judge ruled the U.S. government…
STAT+: Pharmalittle: Pelosi tries last-ditch drug pricing proposal; Merck sees up to $7B in Covid pill sales in 2022
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Here’s how Biden can address high drug prices, without help from Congress
WASHINGTON — If President Biden wants major pharmaceutical industry reforms, he may have to achieve…
STAT+: Alnylam’s longtime CEO to depart, new leader named
John Maraganore, who has been the chief executive of Alnylam for nearly 19 years, is…
STAT+: Pharmalittle: Biden abandons effort to lower drug prices; cheap antidepressant holds promise in fighting Covid
Top of the morning, and a fine one it is. Clear blue skies and crisp…
STAT+: Rafael Pharma drug fails to prolong survival of patients with pancreatic cancer in large study
Rafael Pharmaceuticals said Thursday that its experimental treatment for pancreatic cancer failed to prolong the…
STAT+: Be careful who you sue: CytoDyn knowingly submitted an incomplete drug application to FDA, new documents show
CytoDyn and its CEO Nader Pourhassan have known the company’s long-delayed HIV drug was in…
STAT+: Feds probe Novartis over Entresto marketing and compensation to doctors
In what might become a new scandal for Novartis, federal investigators recently demanded information from…
STAT+: As scientific labs replace offices, pushback is mounting from wary neighbors
The rapid growth of biotech labs in Greater Boston might end up saving the region’s…
STAT+: Pharmalittle: FDA panel votes to OK Covid shots for kids; Merck licenses Covid pill to Medicines Patent Pool
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it…
STAT+: In a groundbreaking move, Merck and the Medicines Patent Pool ink a licensing deal for a Covid-19 pill
In a notable bid to widen access to Covid-19 remedies, Merck (MRK) agreed to license…
STAT+: 6 things to know before the readout of Rafael Pharma’s pancreatic cancer drug study
Pancreatic cancer is hard to detect early and notoriously resistant to treatment, making it the…